ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,962 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentAllschwilInCephalo AG
InCephalo AG Logo
Verified· 2 sources

InCephalo AG

Summary

About the company

The core activity of InCephalo Therapeutics is the development and research of local therapies for neurological diseases, particularly brain cancer. The company focuses on the development of biological drugs specifically designed for local application in the central nervous system (CNS) to minimize side effects and maximize efficacy. The proprietary Compartment Lock technology (C-Lock) enables the local retention of biological drugs in the CNS, prolonging their effect while minimizing systemic exposure.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered5
C-Lock™ Platform
Compartment-locked biologics for local CNS therapies; development of constructs with reduced FcRn binding, prolonged retention in the brain and rapid systemic clearance.
C-Locked Biologics
Local biological therapeutics for brain tumours; precise immune activation without systemic exposure, designed for safe and effective treatment of CNS diseases.
Glioblastoma Therapy (InC01)
Cytokine-based therapy for glioblastoma with local immune activation, increased dosing control and no systemic toxicity; lead asset in clinical development.
Therapies for Paediatric High-Grade Gliomas and DIPG
Planned clinical expansion of the platform for paediatric high-grade gliomas and DIPG based on the C-Lock technology.
Therapies for Neuroinflammation and Neurodegeneration
Potential application of the modular C-Lock platform to conditions beyond tumours, in particular neuroinflammation and neurodegeneration.
Comparisons

InCephalo AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank InCephalo AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of InCephalo AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hegenheimermattweg 167A
4123 Allschwil

At a glance

Legal form
Corporation
UID
CHE-473.675.319
Founded
2021 · 5 years
Last commercial register change
June 10, 2026
Employees
1 to 10

Knowledge

No knowledge articles yet

Once InCephalo AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

AP
Actelion Pharmaceuticals Ltd
Allschwil
MH
Monix Health AG
Allschwil
PS
Pharmatrans Sanaq AG
Allschwil
OA
OncoGenomX AG
Allschwil
IA
INNOSIAMO AG
Allschwil
IA
INOFEA AG
Muttenz
PP
Perseo pharma AG
Muttenz
SF
Stiftung Forschung Klinik Arlesheim
Arlesheim